Cytochrome P450 2C19 (abbreviated CYP2C19), a member of the cytochrome P450 mixed-function oxidase system, is involved in the metabolism of xenobiotics in the body. It is involved in the metabolism of several important groups of drugs including many proton pump inhibitors and antiepileptics. ...
Selective serotonin reuptake inhibitors (SSRIs), such as Citalopram and Escitalopram, are commonly used to treat patients with depressive disorders and, in recent years, they have been increasingly prescribed [2]. Nonetheless, 30–40% of depressed patients treated with SSRIs exhibit partial clinical...
The discovery of compounds decreasing cholesterol levels in 1976 [4,5] has paved the way for a new class of drugs, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase, HMGCR) inhibitors or statins. Goldstein and Brown were the first to describe that patients with familial hypercholest...
autopsies which had been submitted to a systematic toxicological analysis and tested positive for drugs and psychoactive substances metabolised by, or inhibitors/inducers of, CYP2D6, CYP2B6, CYP2C9, and CYP2C19; c. post-mortem interval defined by autopsy as <5 days. Exclusion criteria included ...
The CYP2C19 enzyme contributes to the metabolism of many clinically used drugs, including clopidogrel, voriconazole (VCZ), proton pump inhibitors (PPIs), anti-depressants, carisoprodol, and diazepam [1]. In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC), a shared project between ...